Literature DB >> 34283655

Epitope Mapping of the Anti-CD44 Monoclonal Antibody (C44Mab-46) Using the REMAP Method.

Teizo Asano1, Mika K Kaneko1, Junko Takei1, Nami Tateyama1, Yukinari Kato1,2.   

Abstract

CD44 functions as a major hyaluronan receptor on most cell types, with roles in cell adhesion, migration, proliferation, differentiation, and survival. The CD44 gene comprises 20 exons, with alternative splicing producing many different isoforms. CD44 variant isoforms exhibit tissue-specific expression patterns and have been studied as therapeutic targets for several cancers; therefore, anti-CD44 monoclonal antibodies (mAbs) are useful for investigating CD44 expression in various cancers. Previously, we established an anti-CD44 mAb, C44Mab-46 (IgG1, κ), by immunizing mice with the CD44v3-10 ectodomain. Although C44Mab-46 recognized all CD44 isoforms, the binding epitope of C44Mab-46 has not been determined. In this study, we first checked the reactivity of C44Mab-46 to several CD44v3-10 deletion mutants such as dN79, dN124, dN147, and dN224. We found the N-terminus of the C44Mab-46-binding epitope between residues 147 and 224 of CD44v3-10. We next investigated this epitope using a novel mapping system: RIEDL insertion for epitope mapping (REMAP) method. We constructed 31 CD44 standard (CD44s) mutants where the RIEDL tag was inserted into the expected epitope region in CD44s. We observed that the C44Mab-46 epitope constituted five amino acids: 174-TDDDV-178 of CD44s. Thus, the REMAP method could be used to determine mAb binding epitopes for membrane proteins.

Entities:  

Keywords:  CD44; REMAP method; epitope mapping; monoclonal antibody

Mesh:

Substances:

Year:  2021        PMID: 34283655     DOI: 10.1089/mab.2021.0012

Source DB:  PubMed          Journal:  Monoclon Antib Immunodiagn Immunother        ISSN: 2167-9436


  4 in total

1.  Development of a Novel Anti-EpCAM Monoclonal Antibody for Various Applications.

Authors:  Guanjie Li; Hiroyuki Suzuki; Teizo Asano; Tomohiro Tanaka; Hiroyoshi Suzuki; Mika K Kaneko; Yukinari Kato
Journal:  Antibodies (Basel)       Date:  2022-06-08

2.  SARS-CoV-2-Induced Immunosuppression: A Molecular Mimicry Syndrome.

Authors:  Darja Kanduc
Journal:  Glob Med Genet       Date:  2022-07-14

3.  Development of a Novel Anti-CD44 Monoclonal Antibody for Multiple Applications against Esophageal Squamous Cell Carcinomas.

Authors:  Nohara Goto; Hiroyuki Suzuki; Tomohiro Tanaka; Teizo Asano; Mika K Kaneko; Yukinari Kato
Journal:  Int J Mol Sci       Date:  2022-05-16       Impact factor: 6.208

4.  Defucosylated mouse‑dog chimeric anti‑HER2 monoclonal antibody exerts antitumor activities in mouse xenograft models of canine tumors.

Authors:  Hiroyuki Suzuki; Tomokazu Ohishi; Teizo Asano; Tomohiro Tanaka; Masaki Saito; Takuya Mizuno; Takeo Yoshikawa; Manabu Kawada; Mika K Kaneko; Yukinari Kato
Journal:  Oncol Rep       Date:  2022-07-20       Impact factor: 4.136

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.